VivoSeq
Infectious Disease

Bacterial Pneumonia

52

Pipeline Programs↗

5

Active Trials↗

21

Companies Involved↗

Bacterial Pneumonia is a moderately active landscape with 52 programs across 21 companies. The most active players are Paratek Pharmaceuticals Inc, Meiji Seika Pharma Co., Ltd., Eagle Pharmaceuticals, Inc.. 9 therapies are approved with 31 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

11/100

Mech. Concentration

35/100

Completion Rate

73/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Paratek Pharmaceuticals Inc

1 program

Phase 1M

Meiji Seika Pharma Co., Ltd.

1 program

Phase 1E

Eagle Pharmaceuticals, Inc.

1 program

Phase 2Roche logo

Roche

1 program

Phase 2F

Furiex Pharmaceuticals, Inc

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

32

clinical trials

Completed19 · 59%
Terminated4 · 13%
Recruiting3 · 9%
Withdrawn3 · 9%
Not yet recruiting1 · 3%
Active, not recruiting1 · 3%
Other1 · 3%

Clinical Trials

Trial Activity

32 trials

Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)
Recruiting·—·Phase 4·NCT06804096·160 enrolled
A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia
Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT06841731·100 enrolled
A Prospective, Multinational, Multicenter, Randomized, Sequential, Double-blind, Placebo-controlled, Phase 2a Clinical Trial to Assess the Safety and Pharmacokinetics of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (ABC).
Recruiting·OOmnix Medical Ltd·Phase 2·NCT06087536·54 enrolled
Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
Active, not recruiting·EEagle Pharmaceuticals, Inc.·Phase 2·NCT05776004·276 enrolled
Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
Not yet recruiting·BBioVersys AG·Phase 3·NCT07326540·248 enrolled
Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia
Completed·MMelinta Therapeutics, Inc.·Phase 3·NCT02679573·860 enrolled
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT02493764·537 enrolled
Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00538694
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
Completed·PParatek Pharmaceuticals Inc·Phase 3·NCT04779242·670 enrolled
Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus
Completed·FForest Laboratories·Phase 4·NCT01645735·49 enrolled
A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
Completed·Pfizer logoPfizer·Phase 3·NCT01371838·848 enrolled
Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT03583333·274 enrolled
Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia
Completed·PParatek Pharmaceuticals Inc·Phase 1·NCT04160260·18 enrolled
Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
Completed·MMelinta Therapeutics, Inc.·Phase 2·NCT01168713·132 enrolled
A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia
Completed·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT01886053·189 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)